U.S. approves new Alzheimer's drug developed by Biogen, Japan's Eisai

U.S. regulators on Monday approved a new drug for Alzheimer's disease developed by Biogen Inc. and Japan's Eisai Co., calling it the first therapy to work on the underlying cause of the illness.The drug, named Aduhelm, is the first new treatment greenlit for Alzheimer's since 2003, the U.S. Food and Drug Administration said in a news release. The companies also filed an application for the drug in Japan in December."We believe this first-in-class medicine will transform the treatment of people living with Alzheimer's disease and spark continuous innovation in the years to come," Biogen CEO …READ FULL ARTICLE